Pdt Partners, LLC Annexon, Inc. Transaction History

Pdt Partners, LLC

$1.01 Billion
Q1 2024

A detailed history of Pdt Partners, LLC transactions in Annexon, Inc. stock. As of the latest transaction made, Pdt Partners, LLC holds 39,505 shares of ANNX stock, worth $180,537. This represents 0.03% of its overall portfolio holdings.

Number of Shares

39,505

Holding current value

$180,537

% of portfolio

0.03%

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$4.03 - $7.81 $159,205 - $308,534	39,505 New	39,505 $283,000
Q1 2023 May 15, 2023	SELL	$3.74 - $7.46 $6,178 - $12,323	-1,652 Reduced 14.01%	10,140 $39,000
Q4 2022 Feb 14, 2023	SELL	$4.56 - $6.02 $42,330 - $55,883	-9,283 Reduced 44.05%	11,792 $60,000
Q3 2022 Nov 14, 2022	SELL	$3.75 - $6.63 $254,756 - $450,409	-67,935 Reduced 76.32%	21,075 $130,000
Q2 2022 Aug 15, 2022	SELL	$2.11 - $4.06 $36,859 - $70,924	-17,469 Reduced 16.41%	89,010 $336,000

Q1 2022 May 16, 2022	BUY	$2.73 - $11.94 $256,794 - $1.12 Million	94,064 Added 757.66%	106,479 $291,000
Q4 2021 Feb 14, 2022	BUY	$11.49 - $22.0 $142,648 - $273,130	12,415 New	12,415 $143,000

Others Institutions Holding ANNX

# of Institutions

138

Shares Held

87.3M

Call Options Held

2.54M

Put Options Held

556K

Bain Capital Life Sciences Investors, LLC Boston, MA

8.7M
Shares

$39.8 Million
9.43% of portfolio
Satter Management Co., L.P.

7.41M
Shares

$33.8 Million
59.29% of portfolio
Bvf Inc San Francisco, CA

7M
Shares

$32 Million
1.5% of portfolio
Redmile Group, LLC San Francisco, CA

5.5M
Shares

$25.1 Million
1.56% of portfolio
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct

5.16M
Shares

$23.6 Million
0.09% of portfolio

View Full List

About Annexon, Inc.

Ticker ANNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,617,700
Market Cap $218M
Description
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...

More about ANNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pdt Partners, LLC with notifications on news.

Account